<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39342923</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>Human immunology</Title><ISOAbbreviation>Hum Immunol</ISOAbbreviation></Journal><ArticleTitle>Genetic variations in Interferon-Induced with Helicase C Domain 1: Impact on COVID-19 risk and severity in the Moroccan population.</ArticleTitle><Pagination><StartPage>111149</StartPage><MedlinePgn>111149</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.humimm.2024.111149</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0198-8859(24)00412-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The clinical spectrum of COVID-19 varies considerably, ranging from asymptomatic cases to severe disease and even death. This variability can partly be attributed to genetic differences in genes associated with inflammation and immune responses. Among these genes, Interferon Induced with Helicase C Domain 1 (IFIH1), which codes for a cytoplasmic sensor, plays a crucial role in detecting SARS-CoV-2 viral RNA and initiating the antiviral interferon (IFN) response, thereby constituting a key element of innate immune defense.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">This study aims to examine the association between genetic variants in the IFIH1 gene and susceptibility to, as well as the severity of, COVID-19 in the Moroccan population.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We conducted a case-control study involving 299 COVID-19 positive patients (149 severe, 150 benign) and 145 uninfected-SARS-CoV-2 controls. We determined the genotypes of two functional variants, rs1990760 (Ala946Thr) and rs3747517 (His843Arg), in the IFIH1 gene using predesigned TaqMan real-time allelic discrimination assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our results indicated that the TT genotype of rs1990760 was associated with increased susceptibility to SARS-CoV-2 under a recessive model (odds ratio [OR] = 2.22, 95 % confidence interval [CI] 1.28-3.84, P=0.003). Conversely, the CT genotype appeared to confer protection against SARS-CoV-2 infection (OR=0.58, 95 % CI 0.38-0.91, P=0.016) and COVID-19 severity (OR=0.56, 95 % CI 0.34-0.91, P=0.019). No significant association was found between rs3747517 and the risk of hospitalization or infection susceptibility.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings underscore the significance of genetic variability in the IFIH1 gene in shaping individual responses to SARS-CoV-2 in the Moroccan population.</AbstractText><CopyrightInformation>Copyright © 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aqillouch</LastName><ForeName>Safaa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca 20360, Morocco; Biochemistry, Biotechnology and Immunophysiopathology Research Team, Health and Environment Laboratory, Ain Chock Faculty of Sciences, Hassan II University of Casablanca 20000, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zerrad</LastName><ForeName>Chaimaa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca 20360, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laazaazia</LastName><ForeName>Oumaima</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca 20360, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouladlahsen</LastName><ForeName>Ahd</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service des Maladies Infectieuses, CHU Ibn Rochd, Casablanca 20360, Morocco; Faculté de médecine et de pharmacie, Université Hassan II, Casablanca 20360, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Bissati</LastName><ForeName>Kamal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, The University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akarid</LastName><ForeName>Khadija</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biochemistry, Biotechnology and Immunophysiopathology Research Team, Health and Environment Laboratory, Ain Chock Faculty of Sciences, Hassan II University of Casablanca 20000, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pineau</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institut Pasteur, Université Paris Cité, Unité "Organisation Nucléaire et Oncogenèse", INSERM U993, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benjelloun</LastName><ForeName>Soumaya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca 20360, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezzikouri</LastName><ForeName>Sayeh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca 20360, Morocco. Electronic address: sayeh.ezzikouri@pasteur.ma.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Immunol</MedlineTA><NlmUniqueID>8010936</NlmUniqueID><ISSNLinking>0198-8859</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IFIH1</Keyword><Keyword MajorTopicYN="N">Interferon beta</Keyword><Keyword MajorTopicYN="N">Polymorphism</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>18</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39342923</ArticleId><ArticleId IdType="doi">10.1016/j.humimm.2024.111149</ArticleId><ArticleId IdType="pii">S0198-8859(24)00412-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle>